

Reference number(s)
1694-H

SPECIALTY QUANTITY LIMIT PROGRAM

ZAVESCA (miglustat)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for type 1 Gaucher disease fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication*	Standard Limit	FDA-recommended dosing
Zavesca (miglustat) 100 mg capsules	90 capsules per 30 days	100 mg orally three times a day

*The limit may apply to the generic equivalent medications.

III. REFERENCES

1. Zavesca [package insert]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc.; November 2017.